What does the strongest, most reliable research conclude?
The single most authoritative study on this question is a 2023 Cochrane review, which pooled data from 37 randomized controlled trials involving over 2,300 children [1]. This is the gold standard of medical evidence. The review found high-certainty evidence that omega-3 supplements had no effect on parent-rated total ADHD symptoms, inattention, or hyperactivity/impulsivity compared to placebo. For example, across 16 studies with 1,166 children, the difference in total ADHD symptoms between the omega-3 and placebo groups was essentially zero (a standardized mean difference of -0.08, which is negligible). This means that, on average, a child taking omega-3s would not show any more improvement in core ADHD symptoms than a child taking a placebo.
The Cochrane review did find low-certainty evidence that children taking omega-3s were more likely to be rated as 'improved' by a clinician (about twice as likely, based on 3 studies with 191 children) [1]. However, the authors caution that this finding is weak and inconsistent with the much stronger, larger body of parent-rated data. When the most rigorous, well-controlled studies are considered, the conclusion is clear: omega-3s do not reduce the core symptoms of ADHD.
Why do some studies suggest omega-3s help?
You may have heard that omega-3s can help with ADHD, and that's because some smaller, less rigorous studies have reported positive results. For instance, a 2015 Iranian trial with 85 children found that omega-3s were as effective as the stimulant medication Ritalin at reducing ADHD symptoms [6]. Another 2016 trial with 150 children reported that adding omega-3s to standard medication led to better clinical improvement than medication alone [5]. However, these studies had small sample sizes, short durations (8 weeks), and did not always use the most rigorous methods. When these smaller studies are combined and analyzed in a larger review like the Cochrane meta-analysis, their apparent benefits disappear [1].
A 2022 Italian trial of 160 children, which was well-designed (randomized, double-blind, placebo-controlled), specifically tested an omega-3/6 supplement for inattentive ADHD and found no benefit on the primary outcome [3]. After 6 months, 46.3% of children in the omega-3 group responded to treatment, but so did 45.6% in the placebo group — a virtually identical rate. This directly contradicts the idea that omega-3s are a useful standalone treatment for ADHD symptoms.
Does having low omega-3 levels matter?
Yes, there is a clear link between low omega-3 levels and more severe ADHD symptoms, but this does not mean that supplementing will fix the problem. A 2025 study of 57 children and adults with ADHD found that those with lower omega-3 index (a measure of EPA and DHA in red blood cells) had worse scores on learning and language disorder scales [2]. Similarly, a 2025 cross-sectional study of 211 Palestinian early adolescents found that children with ADHD had significantly lower dietary omega-3 intake than their peers, and that each unit increase in omega-3 intake was associated with a 45% reduction in hyperactive/impulsive symptoms [4].
These findings suggest that omega-3 deficiency may be a contributing factor or a marker of ADHD severity, but they do not prove that correcting the deficiency with supplements will reverse the condition. Think of it like a fever and an infection: a fever is a sign of infection, but taking a fever-reducing pill doesn't cure the infection. The Cochrane review's high-certainty evidence that supplements don't improve symptoms [1] is the strongest argument that low omega-3 levels are a correlation, not a cause that can be easily fixed with a pill.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2015 to 2025, 2 from 2024 or later, 3 in Q1 journals, collectively cited 87 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 59 papers retrieved from a database of over 500 million.
Sources used in this answer
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents
This 2023 Cochrane review (37 trials, >2,300 participants) is the largest and most rigorous analysis here; it found high-certainty evidence that omega-3 supplements had no effect on parent-rated ADHD symptoms, inattention, or hyperactivity compared to placebo, though low-certainty evidence suggested a possible improvement in clinician-rated global symptoms.
A closer look at the role of nutrition in children and adults with ADHD and neurodivergence
This 2025 study of 57 children and adults with ADHD found that lower omega-3 index (blood levels of EPA and DHA) was correlated with worse learning and language disorder scores, but it was a small, observational study that cannot prove causation.
Omega-3/6 supplementation for mild to moderate inattentive ADHD: a randomised, double-blind, placebo-controlled efficacy study in Italian children
This 2022 randomized, double-blind, placebo-controlled trial of 160 Italian children with inattentive ADHD found no benefit of omega-3/6 supplementation on the primary outcome (ADHD-RS inattention score) after 6 months, with response rates nearly identical between groups (46.3% vs 45.6%).
Association between omega-3 fatty acid intake and ADHD symptoms among early adolescents aged 10–12 years: a cross-sectional study in Palestine
This 2025 cross-sectional study of 211 Palestinian early adolescents found that children with ADHD had significantly lower dietary omega-3 intake than peers, and that higher intake was associated with a 45% reduction in hyperactive/impulsive symptoms, but this is an observational association, not a trial of supplementation.
Omega-3 and Zinc supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder.
This 2016 randomized trial of 150 children found that adding omega-3 to methylphenidate led to better clinical improvement than methylphenidate alone, but the effect was not significant on the Conners' scale compared to placebo, and the study was small and short (8 weeks).
Comparison of therapeutic effects of omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder.
This 2015 trial of 85 children found that omega-3 was as effective as Ritalin at reducing ADHD symptoms, but it was a small, short (8-week) study with no long-term follow-up, and its results conflict with larger, more rigorous trials.
Impulsiveness in children with attention-deficit/hyperactivity disorder after an 8-week intervention with the Mediterranean diet and/or omega-3 fatty acids: a randomised clinical trial
This 2021 trial of 60 children found that 8 weeks of omega-3 supplementation (550 mg EPA, 225 mg DHA daily) was associated with a significant decrease in impulsiveness on the Barratt Impulsiveness Scale, but the sample was small and the effect was modest.